The joint venture will focus on genetic testing in the field of reproductive health and carry out in-depth collaboration on a series of projects that leverage Berry Genomics' advanced technology.

Gene technology empowers new markets

The partnership between (Xcelom Limited) and (Ajlan & Bros Medical Company) marks a major step in Berry Genomics' overseas strategy.

As part of the collaboration, the two parties will fully integrate their technology, scientific research, as well as industrial and strategic resources. The joint venture will introduce DNA-based noninvasive prenatal testing (NIPT) and other genetic testing products to the Saudi Arabian and Middle Eastern markets, provide accurate diagnosis and treatment of genetic diseases and improve the quality of local medical services. The two parties will also launch projects such as the creation of local genetic testing laboratories in the future.

In 2016, Saudi Arabia launched "Vision 2030," a strategic framework whose initiatives include the transformation of the country's health sector, such as by expanding the coverage of medical services, improving its quality and efficiency, employing digitization and smart devices and more, creating clear and substantial market potential.

Ajlan Mohammed Alajlan, Deputy Group CEO of Ajlan & Bros Holding, said: "We are very much looking forward to the collaboration with Berry Genomics and bringing China's advanced disease detection and R&D capabilities to Saudi Arabia. We value Berry Genomics' technology and R&D capabilities in professional fields such as gene sequencing and clinical applications. The partnership between the two parties reflects our positive response towards and our implementation of the medical innovation plans included in 'Vision 2030.' We look forward to seeing this joint venture spur the development of the Saudi pharmaceutical and health industries and improve the lives of the Saudi people."

Gao Yang, Chairman and General Manager of Berry Genomics, said: "The establishment of a partnership with a company as strong and capable as Ajlan & Bros Holding is only the first step. Entering overseas markets will encourage us to continue to refine our products and services to suit different groups of people as well as meet a wider range of clinical needs. We hope to safeguard the health of more people around the world with high-quality genetic testing products."